Pharmaceutical

SAR-442970 by Sanofi for Hidradenitis Suppurativa: Likelihood of Approval

SAR-442970 is under clinical development by Sanofi and currently in Phase II for Hidradenitis Suppurativa.

Feb 20, 2024 - 18:00
SAR-442970 is under clinical development by Sanofi and currently in Phase II for Hidradenitis Suppurativa.
Read the original article

Tags:

Previous Article

Ketamine by NRX Pharmaceuticals for Bipolar Disorder (Manic Depression): Likelih...

Next Article

Not Disclosed Neurodegeneration by Eli Lilly and Co for Neurodegenerative Diseas...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Senate committee plans Nov. 8 vote on wide-ranging health care package

STAT+: Senate committee plans Nov. 8 vote on wide-rangi...

Oct 30, 2023

Depression hits new high among Americans, per survey

Depression hits new high among Americans, per survey

May 17, 2023

Leading innovators in anti-viral antigen-based compositions for the pharmaceutical industry

Leading innovators in anti-viral antigen-based composit...

May 8, 2023